Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • RINVOQ Logo

      RA

      HCP RESOURCES

      RINVOQ How To Prescribe Guide

      RINVOQ How To Prescribe Guide

      This guide contains important safety information on dosing, contraindications, precautions, treatment initiation and monitoring criteria. Please read before prescribing RINVOQ by clicking on the link below to download this guide.

      Download
      HCP Educational Brochure

      RINVOQ HCP Educational Brochure

      This education brochure highlights the key risks and requirements for commencing a patient on RINVOQ.

      Download
      HCP Educational Brochure

      RINVOQ Clinical Studies

      An overview of the RINVOQ Phase 3 programme in RA

      View studies

      PATIENT RESOURCES

      patient-booklet

      RINVOQ Patient Booklet

      This patient booklet is a guide for patients who are initiating treatment with RINVOQ. This booklet contains information on how RINVOQ works, how to take it, general precautions and safety information, frequently asked questions and details on the patient portal.

      Download here
      RINVOQ Patient Alert Card

      RINVOQ Patient Card

      This card contains important safety information to be provided to patients who start treatment with RINVOQ.

      Download here
      Patient support

      Explore RINVOQ online resources for your patients

      Help your patients start RINVOQ successfully with these trusted resources.

      Access now

      WARNING: Based on the results from a post-marketing safety study of another JAK inhibitor, RINVOQ should only be used if no suitable treatment alternatives are available in patients:
      • With history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long time smokers).
      • With malignancy risk factors (e.g. current malignancy or history of malignancy).
      • Who are 65 years of age and older.

      Refer to Product Information.

      PBS Information

      RINVOQ: Authority required. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      RINVOQ PI

      AU-RNQR-210080. July 2023